US EditionMore and more older Americans want to know their Alzheimer's status, survey finds
- By 2025, over 7 million Americans who are 65 years old or above are estimated to be affected by Alzheimer's disease, according to the latest report from the Alzheimer's Association.
- This rising prevalence and cost have increased public interest, with nearly 80% of Americans wanting early testing before symptoms affect their daily lives.
- Most Americans support simple tests like blood biomarker screening, and 92% would take medication to slow disease progression despite some risk, while 83% would join clinical trials.
- Annual care costs are projected at $384 billion in 2025, with 19.2 billion unpaid care hours valued at $413 billion, and deaths due to Alzheimer's more than doubled since 2000.
- These findings highlight an urgent need for accessible diagnosis, treatment, and coordinated care efforts to address the growing impact of Alzheimer's disease.
95 Articles
95 Articles
Is the cure for slowing Alzheimer’s a vitamin? Benfotiamine trials underway in South Florida
Four South Florida clinics are enrolling patients in a nationwide trial for a vitamin that may offer a solution for slowing memory loss and halting the progression of Alzheimer’s disease. The trial will study benfotiamine, a laboratory-made form of thiamine, also known as vitamin B1, as a treatment to slow Alzheimer’s disease. Researchers have discovered that thiamine does not enter the brains of people with early Alzheimer’s despite having a su…
Alzheimer's numbers climb in the U.S.
(New York, NY) — There are now more than seven-million Americans living with Alzheimer’s disease. Researchers who worked on the Alzheimer’s Association’s 2025 Disease Facts and Figures report, say that’s the highest number the organization has ever recorded. New York Dr. Nikhil Palekar says two new FDA-approved medications, Lecanemab and Donanemab, are helping to slow the progression of symptoms in people with early stages of the disease. He st…
ABC FOX Montana
More Kids Without Asthma Inhaler After Popular Product Taken Off Market
Key Takeaways
Coverage Details
Bias Distribution
- 70% of the sources are Center
To view factuality data please Upgrade to Premium
Ownership
To view ownership data please Upgrade to Vantage
